CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 1.92B | 1.72B | 1.86B | 1.90B | 1.94B |
| Total Receivables | -- | -- | -- | 27.10M | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 9.88M | 8.93M | 8.83M | 6.21M | 8.25M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 3.50M | 3.50M | 3.50M | -- | -- |
| Total Current Assets | 1.93B | 1.73B | 1.87B | 1.94B | 1.94B |
|
|
|||||
| Total Current Assets | 1.93B | 1.73B | 1.87B | 1.94B | 1.94B |
| Net Property, Plant & Equipment | 255.49M | 262.57M | 269.70M | 277.55M | 284.83M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 9.71M | 10.88M | 28.79M | 27.35M | 27.41M |
| Total Assets | 2.25B | 2.03B | 2.17B | 2.24B | 2.26B |
|
|
|||||
| Total Accounts Payable | 11.80M | 9.75M | 13.06M | 14.71M | 15.58M |
| Total Accrued Expenses | 24.90M | 27.37M | 28.29M | 39.41M | 35.55M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 18.26M | 18.03M | 17.51M | 17.29M | 16.88M |
| Total Finance Division Other Current Liabilities | 64.00M | 49.21M | 60.59M | 16.38M | 21.80M |
| Total Other Current Liabilities | 64.00M | 49.21M | 60.59M | 16.38M | 21.80M |
| Total Current Liabilities | 118.96M | 104.36M | 119.45M | 87.78M | 89.81M |
|
|
|||||
| Total Current Liabilities | 118.96M | 104.36M | 119.45M | 87.78M | 89.81M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 192.77M | 197.43M | 201.85M | 206.41M | 210.66M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 17.60M | 16.80M | 15.64M | 15.77M | 16.00M |
| Total Liabilities | 329.33M | 318.59M | 336.94M | 309.95M | 316.47M |
|
|
|||||
| Common Stock & APIC | 3.73B | 3.42B | 3.33B | 3.30B | 3.26B |
| Retained Earnings | -1.82B | -1.71B | -1.50B | -1.37B | -1.33B |
| Treasury Stock & Other | 4.93M | 3.98M | 4.07M | 1.78M | 10.50M |
| Total Common Equity | 1.92B | 1.71B | 1.83B | 1.93B | 1.94B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.92B | 1.71B | 1.83B | 1.93B | 1.94B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.92B | 1.71B | 1.83B | 1.93B | 1.94B |
|
|
|||||